Researchers from the Centenary Institute, in collaboration with the University of Sydney, have developed a powerful new tool ...

Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the ...

The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is ...

InflaRx’s vilobelimab met the bar for futility in a Phase III trial for the rare skin disease pyoderma gangrenosum.

In recent years, the therapeutic landscape for hematological malignancies has undergone a profound transformation, driven by ...

Pharmacists play a crucial role in managing treatment with chimeric antigen receptor T-cell therapy and bispecific antibodies, focusing on patient selection and side effects, explained Eileen Peng, ...

We treated 428 patients who had active rheumatoid arthritis despite methotrexate therapy with placebo or infliximab, a chimeric monoclonal antibody against TNF-α, in intravenous doses of 3 or 10 ...

In the two decades since a young father was diagnosed with multiple myeloma, clinical trials and advances in treating his ...

CD70 expression increased cytotoxicity of CD70 CAR NK cells against osteosarcoma; however, upregulation of CD70 had no effect on cytotoxicity.

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company’s diversified oncology portfolio at the American Society of ...